



Market Announcement

2 October 2023

Exopharm Limited (ASX: EX1) – Suspension from Quotation

Description

The securities of Exopharm Limited ('EX1') will be suspended from quotation immediately, pending the receipt of an announcement regarding a transaction that could result in a change of its activities.

EX1's securities will remain suspended until it has either complied with Chapters 1 and 2 of the Listing Rules under Listing Rule 11.1.3, or provided ASX with sufficient information to satisfy ASX that it should not exercise its discretion under Listing Rule 11.1.2 to require the transaction to be conditional on approval by EX1's ordinary security holders, and under Listing Rule 11.1.3 to require EX1 to re-comply with Chapters 1 and 2 of the Listing Rules.

Issued by

Tyson Cleghorn

Adviser, Listings Compliance

2 October 2023

Ms Vanessa Nevjestic
Senior Adviser, Listings Compliance (Perth)
ASX Limited

By email: tradinghaltspert@asx.com.au

Dear Ms Nevjestic

VOLUNTARY SUSPENSION REQUEST

Exopharm Limited (the "Company") hereby requests a voluntary suspension of its securities and provides the following information in accordance with Listing Rule 17.2.

The Company requests voluntary suspension in relation to a material acquisition to which Listing Rules 11.1.2 and 11.1.3 will apply.

The Company anticipates the suspension will last until the Company's shareholders approve the material acquisition and the Company is able to re-comply with chapters 1 and 2 of the Listing Rules or otherwise makes an announcement in relation to the material acquisition.

The Company is not aware of any reason why its securities should not be suspended.

The Company is not aware of any other information necessary to inform the market about the voluntary suspension.

Yours faithfully,

EXOPHARM LIMITED

A handwritten signature in blue ink, appearing to be "M. Davies".

Mr Mark Davies

Chair